The purpose of this study was to determine whether asthma control and reduced bronchial responsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS BID or FP BID in adult and adolescent patients with persistent asthma
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
446
Average ICS treatment dose over the treatment period
Time frame: Every 8 weeks through 40 weeks of treatment
Pulmonary function measures
Time frame: Every 8 weeks through 40 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Twice daily dosing
Twice daily dosing
Twice daily dosing
Twice daily dosing
Twice daily dosing
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Jasper, Alabama, United States
GSK Investigational Site
Glendale, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Huntington Beach, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Denver, Colorado, United States
...and 47 more locations